Related Experiment Video
Updated: Jun 21, 2025
An Educational Video Demonstration of How to Prone a Critically Ill Intubated Patient
Published on: November 30, 2022
How international guidelines recommend treating children who have severe COVID-19 or risk disease progression
Joanna Mańdziuk1, Ernest Kuchar1, Magdalena Okarska-Napierała1
1Department of Pediatrics with Clinical Assessment Unit, Medical University of Warsaw, Warsaw, Poland.
Insights
This review summarizes COVID-19 treatment guidelines for children, offering a practical approach to drug selection for severe cases and high-risk pediatric patients. Key antivirals and immunomodulators are discussed.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Pharmacology
- Evidence-Based Medicine
Background:
- COVID-19 presents unique challenges in pediatric populations.
- Management guidelines for pediatric COVID-19 treatment are evolving.
- A consolidated approach to drug therapy is needed for clinicians.
Purpose of the Study:
- To review current knowledge and international guidelines for managing COVID-19 in children.
- To propose a practical drug treatment strategy for pediatric COVID-19.
- To synthesize evidence for effective therapeutic interventions.
Main Methods:
- Analysis of international treatment guidelines from leading scientific bodies.
- Inclusion of guidelines from UK NICE, US NIH, IDSA, and Australian Taskforce.
- Systematic review of drug recommendations for pediatric COVID-19.
Main Results:
- Most pediatric COVID-19 cases require only symptomatic treatment.
- Limited evidence exists for severe or high-risk pediatric cases.
- Consensus exists on nirmatrelvir/ritonavir or remdesivir for prophylaxis in high-risk children.
- Remdesivir is indicated for severe COVID-19.
- Glucocorticosteroids are recommended for patients needing oxygen.
- Tocilizumab or baricitinib are reserved for progressive disease with systemic inflammation.
Conclusions:
- International guidelines offer valuable insights into pediatric COVID-19 drug treatment.
- A degree of consensus exists for managing severe or progressive pediatric COVID-19.
- The synthesized information provides a practical framework for clinicians treating children.
Aim:
This study reviewed the current knowledge and guidelines on managing COVID-19 in children and proposed a practical approach to drug treatment.
Methods:
We analysed international guidelines from four prominent scientific bodies on treating COVID-19 in children. These were the UK National Institute for Health and Care Excellence, the American National Institutes of Health, the Infectious Diseases Society of America and the Australian National Clinical Evidence Taskforce COVID-19.
Results:
Most paediatric patients with COVID-19 only require symptomatic treatment. There was limited evidence on treatment recommendations for children with severe COVID-19 or at risk of disease progression. However, several drugs are available for children and we have summarised the guidelines, in order to provide a concise, practical format for clinicians. All the guidelines agree that nirmatrelvir plus ritonavir or remdesivir can be used as prophylaxis for severe COVID-19 in high-risk patients. Remdesivir can also be used for severe COVID-19 cases. Glucocorticosteroids are recommended, particularly in patients requiring oxygen therapy. Tocilizumab or baricitinib should be reserved for patients with progressive disease and/or signs of systemic inflammation.
Conclusion:
The guidelines provide useful advice and a degree of consensus on specific drug treatment for children with severe COVID-19 or at risk of progression.
More Related Videos
09:03Nasal Brushing Sampling and Processing Using Digital High Speed Ciliary Videomicroscopy – Adaptation for the COVID-19 Pandemic
Published on: November 7, 2020
09:36Halogenated Agent Delivery in Porcine Model of Acute Respiratory Distress Syndrome via an Intensive Care Unit Type Device
Published on: September 24, 2020
Related Concept Videos
01:28Pneumonia IV: Management
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
01:29Acute Respiratory Failure-V
Ensure that patients are monitored continuously for their response to therapy, including changes in...
01:28Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
01:17Transmission-based Precautions I: Contact, Enteric, and Droplets
Contact Precautions:
Contact precautions are the measures taken to prevent the transmission of infectious agents, especially epidemiologically important microorganisms such as MRSA or influenza, primarily transmitted through direct or indirect contact with an...
01:25Transmission-based Precautions II: Airborne and Protective Environment
Airborne precautions:
Use airborne precautions when treating patients known or suspected to have diseases that spread through the air—for example, tuberculosis or measles. These organisms are present in smaller droplets expelled by an infected person and...
01:26Tonsillitis II: Management